GlobeNewswire · Press release
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records
Event records load after the price chart.
Healthcare · Biotechnology
The Quantellect read. The borrow fee is 7.25%. Descriptive summary of the data on this page, not a recommendation.
—
RSI (14) 36.3 (overbought above 70, oversold below 30)
—
FINRA settlement Oct 30, 2026
Price — · As of —
| Range | 6M |
|---|---|
| First date | — |
| Last date | — |
| Open | — |
| High | — |
| Low | — |
| Close | — |
| Volume | — |
| Plotted bars | 0 |
Event records load after the price chart.
| Range | 6M |
|---|---|
| First close | — |
| Last close | — |
| High | — |
| Low | — |
| Volume | — |
AIM · NYSE American · USD
Split-adjusted · volume in shares
— · Notable price movement not available
— · Options flow not available
— · Industry comparison not available
Insufficient coverage
Based on 1 active firms as of Nov 19, 2026 (365-day activity window)
As of Nov 19, 2026 across 0 active firms with targets. Targets are published by third-party analysts, not by Quantellect.
Full analyst forecast →In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.
GlobeNewswire · Press release
GlobeNewswire · Press release
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon
Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.